Do you want to read an article? Please log in or register.
Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
J Allergy Clin Immunol.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB
doi: 10.1016/j.jaci.2018.08.031.
Asthma
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators
doi: 10.1016/
Asthma
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Drug Des Devel Ther.
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
doi: 10.2147/
Asthma
Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab
Respir Med.
Suzukawa M, Matsumoto H, Ohshima N, Tashimo H, Asari I, Tajiri T, Niimi A, Nagase H, Matsui H, Kobayashi N, Shoji S, Ohta K
doi: 10.1016/j.rmed.
Asthma
The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
Respir Res.
Matucci A, Vultaggio A, Danesi R
doi: 10.1186/s12931-018-0859-z.
COMMENTED
Asthma
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
Am J Respir Crit Care Med.
Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, Radford K, Sehmi R, Nair P
doi: 10.1164/
RECOMMENDED
Asthma
Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Van Hulst G, Jorssen J, Jacobs N, Henket M, Louis R, Schleich F, Bureau F, Desmet CJ
doi: 10.1183/13993003.00935-2021
Asthma
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
Drug Des Devel Ther.
Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G
doi: 10.2147/DDDT.S155307.
RECOMMENDED
Asthma
Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ
doi: 10.1016/j.chest.2020.08.2083.